Our patient’s safety is foremost in our minds and MEROVEN is an early adopter of the upcoming EU legislation against falsified medicines. The European Medicine Agency (EMA) has taken measures to help protect patients from falsified medicines and has set new regulations that introduce ‘safety features’ on packaging of medicines for human use.

The EMA and the European Commission have prepared an implementation plan for centrally authorized medicines, to guide applicants and marketing-authorization holders in meeting the requirements of the new Falsified Medicines Directive.

In early compliance with these regulations, MEROVEN has introduced two safety features, a unique identifier (2-dimensional barcode) and an anti-tampering device, to be placed on packaging. While enforcement of these regulations are not scheduled until early 2019, MEROVEN is among the leading manufacturers to adopt such safety features on its packaging of prescription medicines.